[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pmmrmss-advanced-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pmmrmss-advanced-colorectal-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100632178","phase-1-clinical-study-of-msh2---tumor-cell-vaccines-for-advanced-pmmr-colorectal-cancer-patients-100632178",false,"NCT07510308","Clinical Study of MSH2-\u002F- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients","A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of MSH2-\u002F- Tumor Cell Vaccines in Patients With Advanced pMMR Colorectal Cancer.","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years at the time of acquisition informed consent form.\n2. Patients with histologically or cytologically confirmed pMMR colorectal cancer based on molecular typing, who have experienced failure of, are intolerant to, or refuse standard therapy.\n\n   1. For patients with RAS\u002FBRAF wild-type disease who are eligible for targeted therapy, enrollment is permitted only after they have previously received standard regimens containing an anti-EGFR monoclonal antibody or an anti-VEGF monoclonal antibody and subsequently experienced disease progression.\n   2. For patients with a BRAF V600E mutation, enrollment is permitted only after failure of prior treatment with a regimen containing a BRAF inhibitor in combination with chemotherapy.\n   3. For patients who do not meet the above molecular criteria, enrollment is permitted only after failure of at least two prior lines of systemic chemotherapy, including platinum-based agents.\n3. The presence of at least one measurable or evaluable lesion according to RECIST v1.1 criteria.\n4. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-2.\n5. Predicted survival time ≥3 months.\n6. The main organs are functioning well and the following requirements are met within 7 days before receiving treatment:\n\n   ① Hemoglobin (HGB) ≥80 g\u002FL (no blood transfusion within 14 days); Absolute neutrophil count (ANC) \\>1.5×109\u002FL; White blood cell count ≥3.0×109\u002FL; Platelet count (PLT) ≥80×109\u002FL;\n\n   ② Total bilirubin ≤1.5× upper limit of normal value (ULN); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5×ULN; If there was liver metastasis, ALT or AST≤5×ULN;\n\n   ③ Creatinine (SCr) ≤1.5×ULN or creatinine clearance (CRCI) estimated by Cockcroft-Gault formula ≥60 mL\u002Fmin;\n\n   ④ Prothrombin time (PT), international normalized ratio (INR) ≤1.5×ULN (unless anticoagulation with warfarin);\n\n   ⑤ Cardiac function: left ventricular ejection fraction ≥50%. QTcF interval ≤450 ms.\n7. Men of childbearing potential and women of childbearing age voluntarily use effective contraceptive methods (e.g., condoms, intrauterine devices, spermicides) from the time of signing the informed form until 6 months after the completion of vaccination, and contraceptive use is not allowed. Female cancer patients who have a negative pregnancy test and agree not to breastfeed during the study and for at least 18 months after receipt of the trial vaccine;\n8. The washout period of previous anti-tumor therapy should be at least 4 weeks, and the washout period of molecular targeted drugs should be at least 5 half-lives. Palliative radiotherapy needs to have been completed for at least 2 weeks; Chest radiation therapy needed to have been completed for at least 3 months, and major surgery needed to have been completed with at least 4 weeks of recovery.\n\nExclusion Criteria:\n\n1. The patient has a history of other tumors in the past, except for the history of malignant tumors that have been cured and have not recurred within 5 years before screening, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer in situ, and intramucosal cancer of the gastrointestinal tract, which the investigator considers to be eligible for enrollment.\n2. Have any uncontrolled clinical diseases (e.g., diseases of the respiratory system, circulatory system, digestive system, nervous system, hematologic system, urogenital system, endocrine system) or psychiatric or other major medical condition that the investigator considers to interfere with the provision of informed consent, to interfere with the interpretation of the trial results, to pose a risk to the study participants, or to otherwise interfere with the achievement of the study objectives.\n3. Have any active autoimmune disease or a history of autoimmune disease. Participants with asthma for which medical intervention with bronchodilators was required could not be included.\n4. Allergy to the trial drug (including any excipients). Previous history of severe allergy to any drug, food or vaccination, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc.\n5. There are contraindications to subcutaneous injection.\n6. Received prior antitumor therapeutic vaccine or cellular immunotherapy.\n7. Participated in other drug or device clinical trials 4 weeks before screening.\n8. Study participants on systemic therapy with corticosteroids (\\>10 mg\u002F day of prednisone or equivalent doses of other glucocorticoids) or other immunosuppressive agents within 14 days before the first dose of vaccine. Inhaled or topical steroids and adrenal hormone replacement at a therapeutic dose of prednisone of 10 mg or less per day were allowed in the absence of active autoimmune disease.\n9. Before the first dose of the study drug. Any toxic effects from previous antineoplastic therapy have not recovered to NCI CTCAE grade 5.0 ≤1 (any degree of alopecia, other than grade 2 previous platinum-based treatment-related neuropathy).\n10. Has active infection including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.\n11. Have a history of substance abuse or known medical, psychological, or social conditions such as alcohol or drug abuse.\n12. Have received any vaccine within 30 days before receiving the study vaccine or plan to receive any vaccine other than the study vaccine during the study.\n13. The presence of any other factor that was deemed by the investigator to preclude study participant entry into the trial or that study participant had any medical condition that could interfere with the assessment of the safety or efficacy of the study treatment.\n14. Study participants who were unwilling or unable to comply with study requirements.","ALL","18 Years","75 Years",{"count":20,"type":21},9,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to evaluate the safety and tolerability of an MSH2-\u002F- tumor cell vaccine and to explore its preliminary antitumor activity and immunogenicity in adults with advanced proficient mismatch repair (pMMR) colorectal cancer who have failed, are intolerant of, or decline standard systemic therapies at West China Hospital, Sichuan University. The main objectives are to determine the incidence of dose-limiting toxicities (DLTs) and other treatment-emergent adverse events (TEAEs) related to the vaccine (n\u002FN, %, graded per NCI CTCAE v5.0), to assess preliminary antitumor activity (objective response per RECIST v1.1, progression-free survival, and overall survival), and to characterize the vaccine's immunogenicity profile.\n\nThis study using a 3+3 dose-escalation design with three dose levels of the MSH2-\u002F- tumor cell vaccine (1×10\\^7, 2.5×10\\^7, and 5×10\\^7 cells per dose), manufactured under GMP conditions and administered by intradermal injection. Each participant will receive four induction vaccinations (three doses every 2 weeks and a fourth dose 1 month after the third), followed by up to eight booster doses every 4 weeks based on tumor response. Participants will undergo protocol-specified safety monitoring with clinical assessments, laboratory tests, and documentation of all AEs\u002FSAEs, and tumor response will be evaluated regularly by imaging per RECIST v1.1. After treatment completion or discontinuation, participants will enter safety and long-term follow-up for disease status and survival.",[27],"pMMR\u002FMSS Advanced Colorectal Cancer","RECRUITING","2026-06-26",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2026-06-11",{"date":36,"type":21},"2027-10-01",{"name":38,"class":39},"West China Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100587571","phase-2-the-aim-of-this-study-is-to-assess-the-efficacy-and-safety-of-chidamide-regorafenib-in-combination-with-iparomlimab-and-tuvonralimab-for-the-treatment-of-advanced-colorectal-cancer-in-third-line-therapy-and-subsequent-lines-100587571","NCT06930118","The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.","An Exploratory Study Investigating the Combination of Chidamide, Regorafenib, Plus Iparomlimab and Tuvonralimab for the Treatment of Drug-esistant and Efractory Dvanced Colorectal Cancer","Inclusion Criteria:\n\n* Patients with advanced colorectal adenocarcinoma confirmed by histology or cytology;\n* Those who have experienced disease progression or are intolerant to treatment after receiving ≥ 2 lines of systemic standard therapy;\n* Patients must have at least one measurable lesion (according to RECIST 1.1 criteria);\n* Patients who have received local radiotherapy at least 3 weeks before the first drug treatment are eligible for inclusion; however, the lesions evaluated by RECIST must not be within the radiotherapy field;\n* Patients must be at least 18 years old;\n* Performance status ECOG score of 0-1;\n* Expected survival ≥ 12 weeks;\n* Patients must have the ability to understand and voluntarily sign the written informed consent form;\n* Women of childbearing age must have a negative pregnancy test within 7 days before the start of treatment. During the study period, both the patient and the patient's spouse must take contraceptive measures.\n\nExclusion Criteria:\n\n* Patients who have undergone major surgery or suffered severe trauma within 4 weeks prior to the first dose of the study drug;\n* Patients with hypersensitivity to any component of the study protocol;\n* Patients planning to conceive or who are pregnant;\n* Patients with brain metastases and an inability to accurately describe their condition;\n* Patients who have experienced any of the following diseases within 6 months prior to the start of the study treatment: myocardial infarction, severe\u002Funstable angina pectoris, NYHA class 2 or higher congestive heart failure, uncontrolled arrhythmia, etc.;\n* Abnormal laboratory tests:\n\nAbsolute neutrophil count (ANC) \\\u003C 1,500\u002Fmm3; Platelet count \\\u003C 75,000\u002Fmm3; Total bilirubin \\> 1.5 times the upper limit of normal; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> 2.5 times the upper limit of normal (for patients with liver metastases \\> 5 times the upper limit of normal); Creatinine \\> 1.5 times the upper limit of normal;\n\n* Patients who have had other cancers (except advanced colorectal cancer) within 5 years prior to the start of this study treatment. Cervical carcinoma in situ, cured basal cell carcinoma and bladder epithelial tumors are excluded;\n* Patients with a history of drug abuse, drug addiction, or alcohol dependence;\n* Patients without legal capacity or with limited civil capacity;\n* Other conditions that the investigator deems inappropriate for inclusion in the study.",{"count":48,"type":21},60,[50],"PHASE2","Patients with advanced colorectal cancer, particularly those of the pMMR\u002FMSS type, exhibit suboptimal therapeutic responses in the third-line and subsequent treatments. The efficacy of the existing standard treatment regimens is highly restricted. In the CORRECT study, the median overall survival (OS) of regorafenib was 6.4 months, the median progression-free survival (PFS) was 1.9 months, and the objective response rate (ORR) was 1%. In the CONCUR study targeting the Asian population, the median OS of the regorafenib group was 8.8 months, the median PFS was 3.2 months, and the ORR was 4%. In the FRESCO study, the median OS of fruquintinib was 9.3 months, the median PFS was 3.7 months, and the ORR was 4.7%. In the TERRA study, the median OS of trifluridine\u002Ftipiracil (TAS-102) was 7.8 months, the median PFS was 2.0 months, and the ORR was 1.1%. The SUNLIGHT study explored the combined treatment modality of TAS-102 plus bevacizumab, where the median OS of the combined regimen was 10.8 months, the median PFS was 5.6 months, and the ORR was 6.1%. Evidently, the therapeutic efficacy of advanced colorectal cancer in the third-line and beyond has plateaued. In recent years, fundamental research has discovered that epigenetic regulation significantly synergizes with anti-angiogenesis and immune checkpoint inhibition therapy. Small-scale clinical explorations have also indicated favorable efficacy and clinical prospects, warranting further investigation. Hence, we contemplate employing the combination of chidamide, regorafenib, and iparomlimab\u002Ftuvonralimab to investigate its efficacy and safety in the treatment of advanced colorectal cancer in the third-line and beyond, and to explore novel breakthroughs for refractory colorectal cancer after multiple lines of treatment.\n\nThe aim of this study is to assess the efficacy and safety of the combination regimen of chidamide, regorafenib, and iparomlimab\u002Ftuvonralimab in patients with advanced colorectal cancer in the third-line and beyond. The study will be conducted at Shanghai Changzheng Hospital. The study drugs, including chidamide, regorafenib, and iparomlimab\u002Ftuvonralimab, are all commercially available in China.",[53,27],"Advanced Colorectal Cancer in the Third-line Treatment and Beyond",[55],"advanced colorectal cancer","2025-04-08",{"date":58,"type":32},"2025-04-16",{"date":60,"type":21},"2025-04-10",{"date":62,"type":21},"2027-09-30",{"name":64,"class":39},"Shanghai Changzheng Hospital",1]